What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 605-612

  Canut, Andrés ^a   Martín Herrero, Jose E ^b   Labora, Alicia ^a   Maortua, Hiart ^a  

^a HOSPITAL TXAGORRITXU   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

AECOPD; Mathematical models; Resistance

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NONHUMAN; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FORECASTING; HUMANS; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 34548131214     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm228     Document Type: Article

References (45)

1. Miravitiles M, Mayordomo C, Artes M et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo Aereo. Respir Med 1999; 93: 173-9.
2. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969; 280: 397-404.
3. Niederman MS, McCombs JS, Unger AN et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21: 576-91.
4. Ortqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J Suppl 2002; 36: 40-53.
5. Dagan R, Klugman KP, Craig WA et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2002; 47: 129-40.
6. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49 31-40.
7. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration 2005; 72: 561-71.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 1-10.
9. Poole MD. A mathematical therapeutic outcomes model for sinusitis. Otolaryngol Head Neck Surg 2004; 130: 46-50.
10. Anon JB, Jacobs MR, Poole MD et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130: 1-45.
11. Miravitiles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J Suppl 2002; 36: 9s-19s.
12. Papi A, Bellettato M, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-21.
13. Seemungal TA, Harper-Owen R, Bhowmik A et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000; 16: 677-83.
14. Alvarez F, Bouza E, Garcia-Rodriguez JA et al. Second consensus report on the use of antimicrobial agents in exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2003; 39: 274-82.
15. Miravitiles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-6.
16. Stockley RA, O'Brien C, Pye A et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45.
17. Allegra L, Blasi F, de Bernardi B et al. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001; 14: 149-55.
18. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7 589-96.
19. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
20. Jones RN, Pfaller MA, Jacobs MR et al. Cefditoren in vitro activity and spectrum: A review of international studies using reference methods. Diagn Microbiol Infect Dis 2001; 41: 1-14.
21. Lodise TP, Preston S, Bhargava V et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 2005; 52: 45-52.
22. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
23. Soriano F, Granizo JJ, Fenoll A et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE Project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003; 15: 107-12.
24. Soriano F, Granizo JJ, Coronel P et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE Project. Int J Antimicrob Agents 2004; 23: 296-9.
25. Alós JI, Oteo J, Aracil B et al. Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain. J Antimicrob Chemother 2001; 48 141-56.
26. Querol-Ribelles JM, Molina J, Naberan K et al. Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting. Int J Antimicrob Agents 2006; 28: 472-6.
27. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005; 26: 479-85.
28. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7.
29. Karlowsky JA, Kelly LJ, Thomsberry C et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 2002; 19: 21-31.
30. Sader HS, Biedenbach DJ, Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 2003; 47: 361-4.
31. Fluit AC, Verhoef J, Schmitz FJ. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 617-25.
32. Soussy CJ, Nguyen J, Goldstein F et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: A multicentre study. Clin Microbiol Infect 2003; 9: 997-1005.
33. Hoban DJ, Bouchillon SK, Johnson JL et al. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from Europe. Eur J Clin Microbiol Infect Dis 2003; 22: 261-7.
34. Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002; 2: 593-604.
35. Pechere JC, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45: 19-24.
36. Anthonisen P, Riis P, Sogaard-Andersen T. The value of lung physiotherapy in the treatment of acute exacerbations in chronic bronchitis. Acta Med Scand 1964; 175: 715-9.
37. Petersen ES, Esmann V, Honcke P et al. A controlled study of the effect of treatment an chronic bronchitis. An evaluation using pulmonary function tests. Acta Med Scand 1967; 182: 293-305.
38. Elmes PC, King TK, Langlands JH et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965; 2: 904-8.
39. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982; 97: 18-21.
40. Jorgensen AF, Coolidge J, Pedersen PA et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10: 7-11.
41. Saint S, Bent S, Vittinghoff E et al. Antibiotics in chronic-obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-60.
42. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80.
43. Karlowsky JA, Jones ME, Thomsberry C et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005; 40 Suppl 2: 89-98.
44. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis the role of levofloxabin 750 mg. Eur Respir J 2005; 25: 1001-10.
45. Wilson R, Allegra L, Huchon G et al. Short-term, and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64.